FibroGen Inc. (NASDAQ: FGEN), a biopharmaceutical company based in the US, has announced that it has received marketing approval in Macau for its drug roxadustat. The drug is indicated for the treatment of anemia caused by chronic kidney disease (CKD), encompassing both dialysis and non-dialysis patients.
Roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor, has been co-developed with the UK pharmaceutical giant AstraZeneca. The drug has already gained approval in China for the treatment of anemia associated with CKD, marking a significant milestone in addressing this common and serious condition that affects a large patient population.- Flcube.com
